129 related articles for article (PubMed ID: 38311868)
1. Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial.
Ulys A; Jankevicus F; Jievaltas M; Venckus R; Auskalnis S; Kardelis Z; Barisiene M; MacLean CM; van Os S; Larsen F
Prostate; 2024 May; 84(6):584-598. PubMed ID: 38311868
[TBL] [Abstract][Full Text] [Related]
2. Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies.
MacLean CM; Ulys A; Jankevičius F; Saladžinskas Ž; van Os S; Larsen F
Medicina (Kaunas); 2023 Mar; 59(4):. PubMed ID: 37109639
[No Abstract] [Full Text] [Related]
3. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
[TBL] [Abstract][Full Text] [Related]
4. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
5. A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk.
Sannala CKR; MacLean C; Larsen F; van Os S; Jadhav P; Shore N; Morgans AK; Okwuosa T; Gobburu J
Clin Pharmacol Drug Dev; 2024 May; ():. PubMed ID: 38757461
[TBL] [Abstract][Full Text] [Related]
6. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study.
Erb K; Pechstein B; Schueler A; Engel J; Hermann R
Clin Pharmacol Ther; 2000 Jun; 67(6):660-9. PubMed ID: 10872648
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic, Safety, and Pharmacodynamic Properties of Teverelix Trifluoroacetate, a Novel Gonadotropin-Releasing Hormone Antagonist, in Healthy Adult Subjects.
MacLean CM; Godsafe Z; Soto-Forte P; Larsen F
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):257-269. PubMed ID: 34448368
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
9. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
[TBL] [Abstract][Full Text] [Related]
10. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
11. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
[TBL] [Abstract][Full Text] [Related]
12. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.
McLeod D; Zinner N; Tomera K; Gleason D; Fotheringham N; Campion M; Garnick MB;
Urology; 2001 Nov; 58(5):756-61. PubMed ID: 11711355
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.
Gu C; Wang Z; Lin T; Liu Z; Han W; Zhang X; Liang C; Liu H; Yu Y; Xu Z; Liu S; Wang J; Jia L; Yao X; Liao W; Fu C; Tan Z; He G; Zhu G; Fan R; Yang W; Chen X; Liu Z; Zhong L; Shi B; Ding D; Chen S; Wei J; Yao X; Chen M; Lu Z; Xie Q; Hu Z; Wang Y; Guo H; Fan T; Liang Z; Chen P; Wang W; Xu T; Li C; Xing J; Liao H; He D; Wu Z; Yu J; Feng Z; Yang M; Dou Q; Zeng Q; Li Y; Gou X; Zhou G; Wang X; Zhu R; Zhang Z; Zhang B; Tan W; Qu X; Sun H; Gan T; Ye D
Chin Med J (Engl); 2023 May; 136(10):1207-1215. PubMed ID: 37010251
[TBL] [Abstract][Full Text] [Related]
14. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
15. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
16. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
[TBL] [Abstract][Full Text] [Related]
17. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study.
Ozono S; Tsukamoto T; Naito S; Ohashi Y; Ueda T; Nishiyama T; Maeda H; Kusuoka H; Akazawa R; Ito M; Akaza H
Jpn J Clin Oncol; 2017 May; 47(5):438-446. PubMed ID: 28334771
[TBL] [Abstract][Full Text] [Related]
19. Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.
MacLean DB; Shi H; Faessel HM; Saad F
J Clin Endocrinol Metab; 2015 Dec; 100(12):4579-87. PubMed ID: 26502357
[TBL] [Abstract][Full Text] [Related]
20. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
